Status: Recruiting
A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours
Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours
Participants needed: 315
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Orion Corporation, Orion PharmaUpdated: May 8, 2026Locations: 20
Eligibility criteria
Male or female subjects ≥18 years old [+18]
Other malignancy active within the previous 2 years except for basal cell or squ... [+21]